Visanne

Страна: Армения

Язык: английский

Источник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Активный ингредиент:

dienogest (micronised)

Доступна с:

Bayer Weimar GmbH & Co. KG

ИНН (Международная Имя):

dienogest (micronised)

дозировка:

2mg

Фармацевтическая форма:

tablets

Тип рецепта:

Prescription

Характеристики продукта

                                Visanne NL/H/1569/001/II/020_SmPC EU common proposed clean Sep 2015
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Visanne 2 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 2 mg dienogest
Excipient with known effect: each tablet contains 62.8 mg lactose
monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablets
White to off-white, round, flat-faced, bevelled-edge tablets with a
debossed “B” on one side and a diameter
of 7 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of endometriosis.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_Method of administration: _
For oral use.
_Posology _
The dosage of Visanne is one tablet daily without any break, taken
preferably at the same time each day with
some liquid as needed. The tablet can be taken with or without food.
Tablets must be taken continuously without regard to vaginal bleeding.
When a pack is finished the next one
should be started without interruption.
There is no experience with Visanne treatment > 15 months in patients
with endometriosis. Treatment can
be started on any day of the menstrual cycle.
Any hormonal contraception needs to be stopped prior to initiation of
Visanne. If contraception is required,
non-hormonal methods of contraception should be used (e.g. barrier
method).
_Management of missed tablets: _
Visanne NL/H/1569/001/II/020_SmPC EU common proposed clean Sep 2015
2
The efficacy of Visanne may be reduced in the event of missed tablets,
vomiting and/or diarrhea (if occuring
within 3-4 hours after tablet taking). In the event of one or more
missed tablets, the woman should take one
tablet only, as soon as she remembers, and should then continue the
next day at her usual time. A tablet not
absorbed due to vomiting or diarrhea should likewise be replaced by
one tablet.
_ADDITIONAL INFORMATION ON SPECIAL POPULATIONS _
_Paediatric population: _
Visanne is not indicated in children prior to menarche
The safety and efficacy of Visanne was investigated 
                                
                                Прочитать полный документ
                                
                            

Документы на других языках

тонкая брошюра тонкая брошюра русский 20-11-2017

Поиск оповещений, связанных с этим продуктом

Просмотр истории документов